HAIFA, Israel and MIAMI, Nov. 24, 2020 /PRNewswire/ -- INSIGHTEC ®, a global healthcare company focused on the therapeutic power of acoustic energy, today announced that the National Health Service (NHS) England has approved funding for MR-guided Focused Ultrasound for the treatment of medication-refractory Essential Tremor patients from April 2021. The NHS England is the publicly funded healthcare system for England.
Essential Tremor is a neurological condition that causes shaking of the hands, head and voice, but may also cause the legs and trunk to shake. The tremor begins mildly and progresses over time, and in some patients, is severe enough to interfere with daily activities, such as personal care, writing, eating, or getting dressed. Essential Tremor affects an estimated 41 million people around the globe.
"For the approximately 50% of Essential Tremor patients who do not get satisfactory relief from medications, having another accessible treatment option available that is incisionless, and often results in immediate relief, is a major breakthrough," commented Prof Dipankar Nandi, MD, Consultant Neurosurgeon, Imperial College Healthcare NHS Trust, who treated Essential Tremor patients under a clinical trial.
MR-guided Focused Ultrasound uses high intensity sound waves, guided by magnetic resonance imaging, to target and treat the area of brain responsible for the tremor. It is an incisionless treatment option which is often performed in an outpatient setting. Focused Ultrasound treatment is currently being performed at nearly 70 medical institutions across the USA, Europe and Asia.
"St. Mary's in London has been a research partner in the development of this technology and is the first center in the UK to offer Focused Ultrasound for medication-refractory Essential Tremor patients," said Maurice R. FerrĂ© MD, INSIGHTEC CEO and Chairman of the Board of Directors. "Reimbursement in England and around the globe is critical to help people living with debilitating tremor improve their quality of life."
INSIGHTEC is a global healthcare company creating the next generation of patient care by realizing the therapeutic power of acoustic energy. The company's Exablate ® Neuro platform focuses sound waves, guided by MRI, to provide tremor relief to patients with Essential Tremor and Tremor-dominant Parkinson's Disease. Research for future applications in the neuroscience space is underway in partnership with leading academic and medical institutions. INSIGHTEC is headquartered in Haifa, Israel, and Miami, with offices in Dallas, Shanghai and Tokyo.
For more information, please visit: www.insightec.com
This document contains forward-looking statements regarding, among other things, plans, expectations, and future events. In some cases, forward-looking statements can be identified by the following words: "may," "can," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "promise," "continue," "ongoing," or the negative of these terms. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. Any forward-looking statement is based on information available to INSIGHTEC as of the date of the statement. All written or oral forward-looking statements attributable to INSIGHTEC are qualified by this caution. INSIGHTEC does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in INSIGHTEC's expectations.
"Exablate," and "Exablate Neuro," as well as the "INSIGHTEC" logo, whether standing alone or in connection with the word " INSIGHTEC", are protected.
INSIGHTEC Media Contact
G&S Business Communications for INSIGHTEC
Logo - https://mma.prnewswire.com/media/1120780/Insightec_Logo.jpg